NCT03055000View on ClinicalTrials.gov

Safety and Immunogenicity of a First-in-Human Mosquito Saliva Peptide Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

February 15, 2017

Primary Completion Date

December 28, 2018

Study Completion Date

December 28, 2018

Conditions
Mosquito-Borne Disease
Interventions
BIOLOGICAL

AGS-v

AGS-v (unadjuvanted) as a suspension in WFI (0.5mL) on Day 0 and on Day 21

BIOLOGICAL

AGS-v + adjuvant

ISA-51-adjuvanted AGS-v emulsified in WFI (0.5mL) on Day 0 and on Day 21

OTHER

Placebo

WFI (0.5mL) on Day 0 and Day 21

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03055000 - Safety and Immunogenicity of a First-in-Human Mosquito Saliva Peptide Vaccine | Biotech Hunter | Biotech Hunter